舒利迭联合思力华治疗COPD临床效果初步评价及分析

Brief evaluation and analysis of clinical effect by Seretide combined with Spiriva in the treatment of COPD

目的研究观察慢性阻塞性肺疾病(COPD)患者给予沙美特罗替卡松气雾剂(舒利迭)联合噻托溴铵粉吸入剂(思力华)的治疗效果。方法 79例慢性阻塞性肺疾病患者,根据患者入院的单双号数分为对照组(39例)和观察组(40例),对照组患者使用舒利迭进行吸入治疗,观察组在此基础上加用思力华进行治疗。对比两组临床疗效。结果治疗后观察组患者的治疗总有效率97.5%明显高于对照组84.6%,观察组患者的血气分析指标显著优于对照组,观察组患者的肺功能指标改善显著优于对照组,差异均有统计学意义(P<0.05)。结论在慢性阻塞性肺疾病患者的治疗过程中使用舒利迭联合思力华的治疗方式,能够有效提高患者的肺功能,改善患者的生活质量,值得推广应用。

Objective To research curative effect by salmeterol flonase aerosol （Seretide） combined with tiotropium bromide powder inhalation （Spiriva） in the treatment of patients with chronic obstructive pulmonary disease （COPD）. Methods A total of 79 patients with chronic obstructive pulmonary disease were divided by admission order into control group （39 cases） and observation group （40 cases）. The control group received Seretide for inhalation treatment, and the observation group received additional Spiriva for treatment. Clinical effects of the two groups were compared. Results The observation group had much higher total effective rate as 97.5% after treatment than 84.6% of the control group, and its blood gas analysis index and improvements in lung function index were also better than those in the control group. Their differences all had statistical significance （P〈0.05）. Conclusion Combination of Seretide and Spiriva in treating of patients with chronic obstructive pulmonary disease can effectively improve their lung function and quality of life. This method is worthy of promotion and application.